US Bancorp DE Acquires 1,078 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

US Bancorp DE grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 21.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,066 shares of the biopharmaceutical company's stock after acquiring an additional 1,078 shares during the period. US Bancorp DE's holdings in Regeneron Pharmaceuticals were worth $4,321,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in REGN. Proficio Capital Partners LLC grew its position in Regeneron Pharmaceuticals by 92,865.3% in the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company's stock worth $156,284,000 after acquiring an additional 219,162 shares in the last quarter. Worldquant Millennium Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the third quarter worth approximately $127,489,000. KBC Group NV grew its position in Regeneron Pharmaceuticals by 296.7% in the fourth quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company's stock worth $97,338,000 after acquiring an additional 102,198 shares in the last quarter. Icon Wealth Advisors LLC grew its position in Regeneron Pharmaceuticals by 18,342.0% in the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company's stock worth $79,874,000 after acquiring an additional 75,569 shares in the last quarter. Finally, State Street Corp grew its position in Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company's stock worth $5,153,603,000 after acquiring an additional 61,277 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Trading Up 1.7 %

Shares of REGN stock opened at $687.15 on Thursday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20. The stock has a market cap of $75.12 billion, a price-to-earnings ratio of 17.95, a P/E/G ratio of 2.34 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The firm has a fifty day moving average of $696.58 and a 200-day moving average of $857.92.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. During the same quarter in the prior year, the company posted $11.86 EPS. The business's revenue was up 10.3% on a year-over-year basis. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.51%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals's payout ratio is 2.30%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. Piper Sandler reduced their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a research note on Monday, January 27th. Robert W. Baird reduced their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating for the company in a research note on Wednesday, February 5th. Canaccord Genuity Group assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price objective for the company. Finally, Wolfe Research assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an "outperform" rating and a $1,150.00 price objective for the company. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.